Loading
A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting.
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation is a phase 2 interventional study registered as NCT06936644 by Shanghai Chest Hospital, with 39 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-04-30. Interventions recorded: IBI351+AK112. Conditions recorded: KRAS G12C Lung Cancer.
Linked to the drug Fulzerasib because the registry names it among its interventions and KRAS G12C-mutant non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulzerasib, KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares Fulzerasib and the tag pipeline.
Shares Ivonescimab and the tag pipeline.
Shares Ivonescimab and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares Ivonescimab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/